B. Riley Wealth Advisors Inc. Invests $457,000 in Inogen, Inc. (NASDAQ:INGN)

B. Riley Wealth Advisors Inc. bought a new stake in Inogen, Inc. (NASDAQ:INGN - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 56,200 shares of the medical technology company's stock, valued at approximately $457,000. B. Riley Wealth Advisors Inc. owned 0.24% of Inogen as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. purchased a new stake in Inogen in the second quarter valued at approximately $30,000. PNC Financial Services Group Inc. increased its position in shares of Inogen by 2,918.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company's stock worth $43,000 after acquiring an additional 7,646 shares during the period. CWM LLC increased its position in shares of Inogen by 2,185.9% during the second quarter. CWM LLC now owns 6,629 shares of the medical technology company's stock worth $54,000 after acquiring an additional 6,339 shares during the period. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Inogen during the first quarter worth $81,000. Finally, Pitcairn Co. purchased a new stake in shares of Inogen during the first quarter worth $86,000. Hedge funds and other institutional investors own 89.94% of the company's stock.

Inogen Trading Up 0.4 %

Shares of INGN stock traded up $0.04 on Monday, reaching $9.16. 267,124 shares of the stock were exchanged, compared to its average volume of 353,313. The business's 50 day moving average price is $11.02 and its 200 day moving average price is $9.08. The company has a market capitalization of $215.97 million, a price-to-earnings ratio of -2.21 and a beta of 1.04. Inogen, Inc. has a twelve month low of $4.13 and a twelve month high of $13.33.

Inogen (NASDAQ:INGN - Get Free Report) last issued its earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.31. The firm had revenue of $88.77 million during the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative net margin of 28.30% and a negative return on equity of 45.37%. The company's revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.42) earnings per share. Equities research analysts forecast that Inogen, Inc. will post -1.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on INGN shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Inogen in a research report on Wednesday, August 7th. StockNews.com raised Inogen from a "sell" rating to a "hold" rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.